XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Disposition of the Hospital Business - (Tables)
9 Months Ended
Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations The $45,760 gain represents the aggregate consideration of $42,000, transaction fees of $2,928, plus the assets and liabilities either transferred to the Exela Buyer or eliminated by us due to the sale of the Hospital Products, which are listed below.
September 30, 2020
Prepaid expenses and other current assets$(134)
Inventories(4,922)
Goodwill(1,654)
Intangible assets, net(407)
Other non-current assets(1,095)
Total long-term contingent consideration payable14,900 
Net liabilities disposed of6,688 
Aggregate consideration42,000 
Less transaction fees(2,928)
Net gain on the sale of the Hospital Products$45,760 
Schedule of Error Corrections and Prior Period Adjustments The pro forma adjustments are based on available information and assumptions that the Company believes are attributable to the sale.
Unaudited Pro Forma Condensed Combined Balance Sheets
As of December 31, 2019
 As ReportedPro Forma AdjustmentsNotesPro Forma
ASSETS
Cash and cash equivalents$9,774 $12,935 (a)$22,709 
Inventories3,570 (3,570)(b)— 
Prepaid expenses and other current assets4,264 27,500 (c)31,764 
Goodwill18,491 (1,654)(d)16,837 
Intangible assets, net813 (813)(e)— 
Other non-current assets39,274 (9,702)(f)29,572 
Total assets$151,436 $24,696 $176,132 
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current portion of long-term contingent consideration payable$5,554 $(5,054)(g)$500 
Accrued expenses19,810 2,800 (h)22,610 
Long-term contingent consideration payable, less current portion11,773 (11,773)(g)— 
Total liabilities180,635 (14,027)166,608 
Shareholders’ equity (deficit):
Accumulated deficit(391,215)38,723 (i)(352,492)
Total shareholders’ (deficit) equity(29,199)38,723 9,524 
Total liabilities and shareholders’ equity (deficit)$151,436 $24,696 $176,132 
Adjustments to the pro forma unaudited condensed combined balance sheet

(a) This adjustment represents the receipt of $14,500 cash consideration from the Exela Buyer at the closing of the Transaction less $1,565 placed into escrow for the estimated earn outs and royalties payable to Breaking Stick Holdings L.L.C., Horizon Santé FLML, Sarl, Deerfield Private Design Fund II, L.P., all affiliates of Deerfield Capital L.P. ("Deerfield") and Broadfin Healthcare Master Fund ("Broadfin") for the current quarter ended.

(b) This adjustment reflects the elimination of Inventories that were purchased as part of the Transaction.

(c) This adjustment reflects the Transaction consideration in the form of ten monthly installment payments of $2,750 (totaling $27,500) beginning 90 days from the Closing date.

(d) This adjustment reflects the elimination of $1,654 of Goodwill based on the relative fair value of the Hospital Products as a portion of the overall value of the Company.

(e) This adjustment reflects the elimination of the unamortized balance of the Intangible asset on acquired developed technology for Vazculep.

(f) This adjustment reflects the elimination of $1,228 of other long-term assets and $8,474 of deferred tax assets at December 31, 2019. The eliminated deferred tax assets are tax attributes of the Hospital Products.

(g) This adjustment reflects the elimination of short and long term related party payables, less the expected amounts due to Deerfield and Broadfin after taking into consideration the escrow discussed in Note (a). As part of the Transaction, the buyer agreed to assume the quarterly earn-out and royalty payments for periods after the close of the Transaction. The Company will no longer be responsible for these payments.

(h) This adjustment reflects the estimated transaction fees payable related to the Transaction.

(i) This adjustment reflects the estimated gain of $38,723 arising from the Transaction for the year ended December 31, 2019. This estimated gain has not been reflected in the pro forma unaudited condensed combined statements of loss as it is considered to be nonrecurring in nature. No adjustment has been made to the sale proceeds to give effect to any potential post-closing adjustments under the terms of the Purchase Agreement.


Unaudited Pro Forma Condensed Combined Statement of Income (Loss)
Nine Months Ended September 30, 2020
 As ReportedPro Forma AdjustmentsNotesPro Forma
Product sales$22,334 $(22,175)(j)$159 
Total operating expense2,259 (8,489)(k)(6,230)
Operating income20,075 (13,686)6,389 
Income (loss) before income taxes$9,048 $(13,251)(l)$(4,203)


Unaudited Pro Forma Condensed Combined Statement of Loss
Nine Months Ended September 30, 2019
 As ReportedPro Forma AdjustmentsNotesPro Forma
Product sales$48,220 $(48,007)(j)$213 
Total operating expense64,985 (14,398)(m)50,587 
Operating loss(16,765)(33,609)(50,374)
Loss before income taxes$(26,846)$(33,113)(n)$(59,959)
Adjustments to the pro forma unaudited condensed combined statements of income (loss)

(j) This adjustment reflects Product sales attributable to the Hospital Products.

(k) This adjustment reflects the following estimated expenses attributable to the Hospital Products:

Cost of products of $3,540.
Research and Development expenses of $407.
Selling, general and administrative expenses of $809.
Intangible asset amortization on acquired development technology for Vazculep of $406.
Changes in fair value of related party contingent consideration of $3,327. The Company will no longer be responsible for these payments.

(l) This amount reflects the adjustments noted in (j) and (k) above, as well as estimated Changes in fair value of related party payable of $435 attributable to the Hospital Products. The Company will no longer be responsible for these payments.

(m) This adjustment reflects the following estimated expenses attributable to the Hospital Products:

Cost of products of $8,972.
Research and Development expenses of $1,604.
Selling, general and administrative expenses of $828.
Intangible asset amortization on acquired development technology for Vazculep of $610.
Changes in fair value of related party contingent consideration of $2,384. The Company will no longer be responsible for these payments.

(n) This amount reflects the adjustments noted in (j) and (m) above, as well as the reversal of estimated Changes in fair value of related party payable of $496 attributable to the Hospital Products. The Company will no longer be responsible for these payments.